Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 4/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPY1R | P25929 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4103999 | 1.00 | ABCB1 (0.43) | ABCB1PTPN1MEN1KMT2ANPY1R | |
| SCHEMBL4094450 | 0.83 | HCRTR1 (0.32) | KMT2ASMN1; SMN2 | |
| SCHEMBL4094454 | 0.83 | HCRTR1 (0.32) | KMT2ASMN1; SMN2 | |
| SCHEMBL14493699 | 0.78 | ABCB1 (0.45) | ABCB1PTPN1MEN1KMT2ANPY1R | |
| SCHEMBL13800027 | 0.76 | ABCB1 (0.46) | ABCB1NPY1RSMN1; SMN2MMP2MMP13 | |
| SCHEMBL13320401 | 0.73 | ABCB1 (0.56) | ABCB1PTPN1SMN1; SMN2CYP2C19 | |
| SCHEMBL4095188 | 0.70 | ABCB1 (0.54) | ABCB1PTPN1 | |
| SCHEMBL4102929 | 0.68 | ABCB1 (0.55) | ABCB1PTPN1MEN1KMT2ACYP2C19 | |
| SCHEMBL2840420 | 0.68 | ABCB1 (0.55) | ABCB1PTPN1MEN1KMT2ACYP2C19 | |
| SCHEMBL14493816 | 0.68 | ABCB1 (0.48) | ABCB1PTPN1NPY1RSMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | GAA, TFPI, DBI | ABCB1 972/4885PTPN1 3687/4885MEN1 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.